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■ INTRODUCTION
Thermophilic Campylobacter species, especially C. jejuni and
C. coli, are among the main agents of gastrointestinal infections in
developed countries (2, 12, 29). Campylobacter also poses an
emerging public health problem in developing countries (13, 19,
20, 32). Most cases of Campylobacter gastrointestinal infections
do not require antimicrobial treatment, being brief, clinically mild,
and self-limiting. However, complications such as severe cases of
enteritis or septicemia may occur and require treatment.
Macrolides and fluoroquinolones (FQs) are the most useful
antimicrobial drugs for Campylobacter infections, but resistance
has been reported to be increasing (12, 19, 26, 29).
Contaminated food is the usual source of human infection and
poultry products are considered to be the main cause of food-
related infection in humans (4). The link between the use of
antimicrobial agents as growth promoter or in veterinary medicine
and the emergence of resistance among Campylobacter from
different animal source has been previously reported (2). The
spread of antimicrobial-resistant strains in the food chain has
raised concerns that treatment of human infections will be
compromised.
In Senegal, a modern poultry production sector is expanding around
Dakar, its capital, in order to rapidly supply the fast-growing urban
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Summary
Campylobacter resistance to antimicrobial agents appears as an emerging
public health problem in industrialized countries, but, on the other hand, only
few data on the subject are available in developing countries. To assess
antibiotic susceptibility of Campylobacter strains in Senegal, skin samples
were collected from 250 chicken carcasses from January 2001 to October
2002. Among 204 Campylobacter strains isolated, two species were
identified: C. jejuni (59%) and C. coli (41%). In vitro susceptibility to five
antimicrobial drugs (amoxicillin, amoxicillin-clavulanic acid, erythromycin,
nalidixic acid and ciprofloxacin) was determined by the E-test method.
Minimum inhibitory concentrations (MICs) showed 34% of Campylobacter
isolates were ciprofloxacin resistant with a high level of resistance (MIC ≥ 32
mg/l) in 25% of both species. Cross-resistance between nalidixic acid and
ciprofloxacin was found in 96% of quinolone-resistant strains. The level of
amoxicillin resistance was statistically higher for C. coli than for C. jejuni
(20.2 versus 10.8%), but all the strains were susceptible to amoxicillin
combined with clavulanic acid. Both species showed low resistance to
erythromycin. Multiresistant phenotype to three of the drugs tested was found
in 9.8% of the strains: 15.5% of C. coli strains and 5.8% of C. jejuni strains.
No strain was resistant to four or more of the drugs studied. Further studies
appear necessary to evaluate antibiotic resistance of Campylobacter isolated
in human and animal samples in order to control the emergence of new
multidrug-resistant strains in Senegal.
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human population with animal protein. Poultry farmers use
antibiotics to fight diseases. Because growing scientific evidence
shows that the use of antimicrobial agents in veterinary medicine
results in development of resistant pathogenic bacteria (1), the
authors’ objective was to assess the frequency of antimicrobial
resistance of Campylobacter strains isolated from “modern” poultry
meat.
■ MATERIALS AND METHODS
Specimen collection and isolation
From January 2001 to October 2002, 250 chicken carcasses were
collected from slaughterhouses and retail shops in Dakar. The
carcasses were immediately brought back to the laboratory in cool
boxes (+4°C). Samples of neck skin (10 g) were taken from each
carcass and added to 90 ml of Preston broth with Preston antibiotic
supplement1 (Oxoid laboratory, England) and incubated at 42°C
during 24 h under microaerophilic conditions (Campygen, Oxoid
laboratory, England). Each sample was then streaked onto Virion
plates (Mueller Hinton agar, Merck, Germany; Bacto agar, Difco
laboratory, USA; with 5% of defibrinated horse blood, AES
laboratory, France) and onto Karmali plates (Oxoid laboratory,
England). Plates were incubated at 42°C under microaerophilic
conditions for 48 h.
Identification of isolates
Isolates were identified using a commercial identification method
(API Campy®, bioMérieux, France). Identification of every isolate
was confirmed by a multiplex PCR, using specific primers of
Campylobacter genus (MD16S1, MD16S2), C. jejuni species
(MDMapA1, MDMapA2) and C. coli species (COL3, MDCOL2)
(10). Briefly, Campylobacter colonies from blood agar plate were
suspended in 0.2 ml TE buffer. Cells were lysed by heating at 95°C
for 10 min and cellular debris were removed by centrifugation at
5000 g for 10 min. The supernatant was used as source of template
for DNA amplification. Each multiplex PCR tube contained 200 µM
deoxynucleoside triphosphate, 2.5 µl of 10X reaction buffer, 20 mM
MgCl2, 0.11 µM Campylobacter genus primers, 0.42 µM C. jejuni
primers and 0.42 µM C. coli primers. Template DNA (3 µl) was
added and the volume adjusted with sterile water to obtain 30 µl.
DNA amplification was carried out in a Perkin-Elmer 9600®
thermocycler using an initial denaturation step at 95°C for 10 min,
followed by 35 cycles. Cycling conditions were as follows:
denaturation, 95°C for 30 s; annealing, 59°C for 90 s; extension,
72°C for 1 min. After the last cycle, a final extension step at 72°C for
10 min was added. Ten microliters of PCR product were analyzed by
gel electrophoresis (1.5% gel agarose). Gels were stained with
ethidium bromide at 0.5 µl/ml and visualized by UV
transillumination. A 100-bp DNA ladder (Amersham Biosciences,
France) was used as size marker. Negative controls were added in
each run. Positive PCR controls consisted of C. jejuni subsp. jejuni
ATCC 49943 and C. coli ATCC 49941.
Susceptibility testing
Several colonies of each strain were suspended in 5 ml of Mueller-
Hinton broth to achieve turbidity equal to 0.5 MacFarland standard.
The suspensions were inoculated with sterile swabs onto Mueller-
Hinton agar with 5% sheep blood. After application of E-test® strips
(AB Biodisk, Sweden) plates were incubated at 37°C for 48 h under
microaerophilic atmosphere. Minimum inhibitory concentrations
(MICs) were read according to the recommendations of the
manufacturer by two different readers. Breakpoints were those
recommended by the Antimicrobial Committee of the French Society
for Microbiology (33). Breakpoints for resistance susceptibility were
higher than 16 mg/l for amoxicillin, than 16/2 mg/l for amoxicillin-
clavulanic acid, than 4 mg/l for erythromycin, than 16 mg/l for
nalidixic acid, and than 2 mg/l for ciprofloxacin. 
Statistical analysis
Data were entered and analyzed with SPSS, version 10 (SPSS,
Chicago, USA). The χ2 test and Fisher’s exact two-tailed test were
used for statistical analysis of the significant difference of
resistance rates. An α of 0.05 was used for statistical significance.
■ RESULTS
Campylobacter was isolated from 81.6% of the samples. C. jejuni
was the most prevalent species (59% C. jejuni versus 41% C. coli).
Susceptibility testing 
The results of antimicrobial susceptibility testing for C. coli and
C. jejuni are shown in Table I. The resistance rate to amoxicillin in
C. coli and C. jejuni was 20.2 and 10.8%, respectively. Among 
1 Polymyxine B (2500 UI); Rifampicine (5 mg), Trimethoprim (5 mg), Cycloheximide (50 mg)
Campylobacter coli (N = 84) Campylobacter jejuni (N = 120)
Antibiotic MIC50* MIC90 Range Resistant (%) MIC50 MIC90 Range Resistant (%)
Amoxicillin 8 256 0.5–256 20.2 4 32 0.125–256 10.8
Amoxicillin + 2 8 0.5–8 1 2 0.094–8
clavulanic acid
Erythromycin 0.5 1 0.064–>256 4.7 0.5 2 0.094–>256 3.3
Nalidixic acid 2 >256 0.5–>256 34.5 2 >256 0.75–>256 31.6
Ciprofloxacin 0.094 >32 0.032–>32 34.5 0.125 >32 0.045–>32 30.8
Table I
Antimicrobial susceptibility of Campylobacter coli and C. jejuni strains
isolated from chicken carcasses in Senegal
* Minimum inhibitory concentrations (mg/l)
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C. coli, MICs of all resistant strains were higher than 256 mg/l.
Among C. jejuni, MICs of 46% of amoxicillin-resistant strains
were higher than 256 mg/l. In addition, amoxicillin MIC90 was
statistically higher for C. coli than for C. jejuni. No strains
resistant to amoxicillin-clavulanic acid were observed. For
amoxicillin high level resistant strains (MIC > 256 mg/l),
amoxicillin-clavulanic acid MIC was between 2/1 and 8/4 mg/l in
both species. The overall resistance rate to erythromycin was 
4.7% for C. coli and 3.3% for C. jejuni without any significant
difference between the two species.
Resistance rates to nalidixic acid in C. coli and C. jejuni were 34.5
and 31.6%, respectively. Among these resistant strains, 55.2% of
C. coli and 68.5% of C. jejuni exhibited MICs higher than 256
mg/l. For both species, MIC90 was higher than 256 mg/l.
Compared to nalidixic acid, quite similar resistance rates to
ciprofloxacin were observed with 34.5 and 30.8% for C. coli and
C. jejuni, respectively. Ciprofloxacin MIC was higher than 32 mg/l
for 25% isolates in both species. Among Campylobacter-resistant
strains, 75.8% of C. coli and 78.3% of C. jejuni had ciprofloxacin
MICs higher than 32 mg/l. Furthermore, 90% of the isolates were
inhibited with MICs higher than 32 mg/l for C. coli and C. jejuni.
For both species, MIC90 was higher than 32 mg/l. 
Coresistant and multiresistant isolates
Drug resistance to one or more drugs was detected in over 38% of
the strains (Table II). Among them, C. coli and C. jejuni, 41.7 and
36.7% of the strains, respectively, exhibited resistance to the tested
antibiotics. Among C. coli and C. jejuni, 33.4 and 30%,
respectively, were resistant to both quinolones (nalidixic acid and
ciprofloxacin). A cross-resistance between nalidixic acid and
ciprofloxacin was found for all isolates (96%) except for one strain
of C. jejuni and one strain of C. coli, which showed a nalidixic
acid-resistant ciprofloxacin-susceptible phenotype. Table III shows
a comparison between nalidixic acid MICs and ciprofloxacin
MICs for cross-resistant isolates: 46.5% of C. coli strains and
63.8% of C. jejuni strains exhibited a high level of resistance to
both quinolones with MICs higher than 256 mg/l for nalidixic acid
and 32 mg/l for ciprofloxacin. Multiresistance, defined as
resistance to three or more of the drugs tested, was found in 9.8%
of Campylobacter strains: 15.5% were C. coli strains and 5.8%
were C. jejuni strains. No strain was resistant to four or five drugs.
The only multidrug-resistant phenotype was amoxicillin, nalidixic
acid and ciprofloxacin in both species.
■ DISCUSSION
In Senegal, beside traditional poultry production, modern poultry
production is expanding around Dakar. Senegalese poultry farmers
try to minimize the impact of diseases on their production with
huge amounts of antibiotics, like in Europe or the United the
States. Considering the growing prevalence of resistant strains in
industrialized countries, antimicrobial drugs must be used very
carefully in Senegal.
In the present survey, 81.6% of chicken carcasses were
contaminated with Campylobacter. In developed countries, several
studies have also reported high levels of Campylobacter isolation
from chicken carcasses and retailed chickens: 46% in Germany
(4), 46% in Japan (23) and from 73% to 100% in the USA (40).
Although little information is available from developing countries,
the present results are consistent with those from Kenya and China
where thermophilic Campylobacter has been isolated from 77 and
76% of chicken samples, respectively (24, 31). As reported by
several studies, Campylobacter isolated from animals may
contaminate humans either by direct ingestion of undercooked
food or by cross-contamination of raw poultry to other foods
caused by non hygienic handling such as unwashed hands or dirty
utensils (18, 22). As already reported (28), C. jejuni was more
frequently isolated than C. coli (59 versus 41%). This phenomenon
is easily explained by the fact that C. coli is mainly associated with
pigs (3).
Because no great discrepancies have been observed between
double dilution agar and E test according to Baker et al. (5) and
Funke et al. (14), the authors used the E test for susceptibility
testing. This method is reliable, technically simple, and needs no
special equipment (13). In some countries FQ resistance rates were
similar between strains isolated from poultry meat and from man
(17, 19, 29), highlighting the need to carefully monitor resistance
in human and animal samples.
In the present survey, high resistance rates to quinolones were
observed in both species isolated from chicken samples. This high
resistance rate was similar to those observed in several European
countries (26) or in Japan (9). As reported by Saenz et al. in Spain
(29), a cross-resistance was observed between nalidixic acid and
ciprofloxacin. But unlike Thwaites and Frost in the United
Kingdom (37), Campylobacter strains with a high level of
resistance to both quinolones were predominant. Nevertheless,
rates of resistance to ciprofloxacin observed in the present study
appeared lower than those described in Belgium (39), Spain (29)
Number of resistant strains (%)
Phenotype Num. C. coli (n = 84) C. jejuni (n = 120)
0 49 (58.3) 76 (63.3)
AMX 1 2 (2.4) 3 (2.5)
CIP 1 1 (1.2) 0
ERY 1 1 (1.2) 0
AMX ERY 2 2 (2.4) 3 (2.5)
ERY NAL 2 1 (1.2) 1 (0.8)
NAL CIP 2 15 (17.9) 30 (25.0)
AMX NAL CIP 3 13 (15.5) 7 (5.8)
Table II
Distribution of Campylobacter strains depending 
on their resistance to antibiotics
AMX = amoxicillin; CIP = ciprofloxacin; ERY = erythromycin; NAL = nalidixic acid
Number of isolates (%)
Nalidixic Ciprofloxacin C. coli C. jejuni
acid MICs* MICs (N = 28) (N = 36)
>16–≤256 >2–≤32 7 (25) 6 (16.7)
>32 8 (28.5) 6 (16.7)
>256 >2–≤32 0 (0) 1 (2.8)
>32 13 (46.5) 23 (63.8)
Table III
Comparison between nalidixic acid MICs 
and ciprofloxacin MICs for cross-resistant
Campylobacter coli and C. jejuni isolates
* Minimum inhibitory concentrations (mg/l)
Sensibilité de Campylobacter aux antibiotiques au Sénégal
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or Lebanon (35), where they ranged from 61 to 100%. By contrast,
no Campylobacter strains were found ciprofloxacin resistant in
Chile (13). 
Since 1991, when Endzt et al. (11) identified the first quinolone-
resistant Campylobacter strains in C. jejuni and C. coli in the
Netherlands, Campylobacter resistance to FQ has been on the
increase throughout the world (12, 29). The percentage of
ciprofloxacin-resistant strains in man increased in Spain from 0-3%
in 1989 to 30-50% in 1991 after licensing the use of enrofloxacin in
1990 in animal husbandry (30). During this period, the same
evolution was observed in The Netherlands (11), Finland (27) and
Canada (15). Likewise in England, before the introduction of FQ in
veterinary medicine, a study showed that domestically-bred poultry
were less contaminated by ciprofloxacin-resistant strains than those
imported from countries where the use of FQ was legal (16). Thus,
this major development of FQ-resistant strains in humans and
animals seems related to the introduction of FQ in veterinary
medicine (11, 29). 
The speed at which the level of resistance to nonfluorinated
(nalidixic acid) and fluorinated (ciprofloxacin) quinolones (34
versus 31%) has been reached may be related to the mechanisms
by which quinolone resistance involves a single chromosomal
mutation on the targets of quinolone action (DNA gyrase, DNA
topoisomerase IV) (12, 25). In Senegal, FQs (norfloxacin,
enrofloxacin) were introduced in veterinary medicine in 1996 in
poultry production to treat respiratory and intestinal diseases as
salmonellosis or colibacillosis. Since 2000, they became first line
molecules because of treatment failures with other antibiotic drugs.
According to observations from other reports and despite the
absence of previous studies on antibiotic resistance in Senegal, the
high prevalence of FQ resistance could thus be related to the
introduction of FQs in the country especially for poultry
production (21). As in developed countries, FQ resistance may
soon become a public health problem.
High levels of amoxicillin resistance were found, particularly in 
C. coli strains. Campylobacter resistance to penicillin A has been
reported in previous studies with resistance rates never exceeding
39% (3, 9, 13, 29). However, in Senegal, amoxicillin was rarely
used for treatment of pasteurellosis or salmonellosis in poultry
production. Resistance is usually associated with beta-lactamase
production but other mechanisms of resistance could be involved,
such as modified penicillin-binding proteins or impermeability
(29, 34). As reported in other studies, most of the isolates of the
present survey showed high susceptibility to amoxicillin-
clavulanic acid (35). Clavulanic acid inhibits some beta-lactamases
and has been claimed to have intrinsic antibacterial activity against
Campylobacter (36).
Among the stains isolated, 4.7% of C. coli and 3.3% of C. jejuni
strains were resistant to erythromycin. This appeared much lower
than results from Nigeria, where resistance rate reached 40.4%
among animal strains (32). In the present study, erythromycin-
resistance rates were similar in both species, contrary to results from
surveys conducted in Spain (17 and 83% of resistance in C. jejuni
and C. coli, respectively; 29) or in Vietnam (17 and 50% of
resistance in C. jejuni and C. coli, respectively; 19). This difference
may be explained by the introduction in these countries of tylosin,
especially used as growth promoter in the pig industry (39). In
Senegal, macrolides were not used as growth promoters in poultry
production; they were only used for treatment of some respiratory
diseases such as chronic respiratory diseases. Resistance to
erythromycin is chromosomally mediated and is due to the alteration
of the ribosome (12), but natural resistance as efflux pump has been
observed too (8).
To the five most relevant antimicrobial drugs selected for
campylobacteriosis treatment, seven resistance patterns were
observed, but only 9.8% of total strains were resistant to three
drugs. None were resistant to four or more drugs. The present
results were much lower than those reported from Belgium (39) or
Spain (29). However, consistently with these studies, C. coli
exhibited more multidrug-resistant strains than C. jejuni in the
present survey.
This study is the first to highlight the decrease of antibiotic
susceptibility of Campylobacter isolated from chicken in Senegal.
Many reasons explain this situation; among others, there is the lack
of information among poultry farmers and veterinary surgeons on
the use of antibiotics and on drug resistance, the inordinate use of
antibiotics due to the high prevalence of infectious diseases among
flocks, and the difficulty to perform large antimicrobiological
studies.
However, as everywhere else in the world, the increase of
Campylobacter-resistant strains seems to be related to the amounts
of antibiotics used in animals (38). Thus, to prevent transfer of
resistant bacteria or resistance genes from animals to humans via
the food chain (6) in Senegal, measures to be implemented are the
same as the ones in developed countries: reduction of the use of
antibiotics (antibiotics should not be available over the counter in
order to avoid self medication), restricting their use to encourage
narrow-spectrum specific antibiotic therapy instead of broad
spectrum antimicrobials (7), and replacement of antibiotics with
improvements in hygiene and flock management.
Consequently, it would be useful to set up an epidemiological
surveillance network to monitor antimicrobial resistance in
bacteria of animal origin. The authors also recommend conducting
further antimicrobial-resistance studies among Campylobacter
isolated from human and animal samples in order to control the
emergence of a new public health problem in Senegal.
Acknowledgments
The authors are grateful for the help COTAVI provided in the
field. This work was sponsored by the French Embassy in Dakar
(Senegal).
REFERENCES
1. AARESTRUP F.M., BAGER F., JENSEN N.E., MADSEN M., MEYLING
A., WEGENER H.C., 1998. Resistance to antimicrobial agents used for
animal therapy in pathogenic-, zoonotic- and indicator bacteria isolated
from different food animals in Denmark: a baseline study for the Danish
Integrated Antimicrobial Resistance Monitoring Programme (DANMAP).
APMIS, 106: 745-770.
2. AARESTRUP F.M., ENGBERG J., 2001. Antimicrobial resistance of
thermophilic Campylobacter. Vet. Res., 32: 311-321.
3. AARESTRUP F.M., NIELSEN E.M., MADSEN M., ENGBERG J., 1997.
Antimicrobial susceptibility patterns of thermophilic Campylobacter spp.
from humans, pigs, cattle, and broilers in Denmark. Antimicrob. Agents
Chemother., 41: 2244-2250.
4. ATANASSOVA V., RING C., 1999. Prevalence of Campylobacter spp.
in poultry and poultry meat in Germany. Int. J. Food Microbiol., 51:
187-190.
5. BAKER C.N., STOCKER S.A., CULVER D.H., THORNSBERRY C.,
1991. Comparison of the E Test to agar dilution, broth microdilution, and
agar diffusion susceptibility testing techniques by using a special
challenge set of bacteria. J. Clin. Microbiol., 29: 533-538.
6. BARTON M.D., 2000. Antibiotic use in animal feed and its impact on
human health. Nutr. Res. Rev., 13: 1-22.
7. BARTON M.D., HART W.S., 2001. Public health risks: antibiotic
resistance. Asian-Aust. J. Anim. Sci., 14: 414-422.
Sensibilité de Campylobacter aux antibiotiques au Sénégal
263
R
ev
ue
 É
le
v.
 M
éd
. v
ét
. P
ay
s 
tr
op
., 
20
02
, 5
5 
(4
) :
 2
59
-2
64
8. CHARVALOS E., TSELENTIS Y., HAMZEHPOUR M.M., KOHLER T.,
PECHERE J.C., 1995. Evidence for an efflux pump in multidrug-resistant
Campylobacter jejuni. Antimicrob. Agents Chemother., 39: 2019-2022.
9. CHUMA T., IKEDA T., MAEDA T., NIWA H., OKAMOTO K., 2001.
Antimicrobial susceptibilities of Campylobacter strains isolated from
broilers in the southern part of Japan from 1995 to 1999. J. vet. Med.
Sci., 63: 1027-1029.
10. DENIS M., REFREGIER PETTON J., LAISNEY M.J., ERMEL G.,
SALVAT G., 2001. Campylobacter contamination in French chicken
production from farm to consumers. Use of a PCR assay for detection
and identification of Campylobacter jejuni and C. coli. J. Appl.
Microbiol., 91: 255-267.
11. ENDTZ H.P., MOUTON R.P., VAN DER REYDEN T., RUIJS G.J.,
BIEVER M., VAN KLINGEREN B., 1990. Fluoroquinolone resistance in
Campylobacter spp. isolated from human stools and poultry products.
Lancet, 335: 787.
12. ENGBERG J., AARESTRUP F.M., TAYLOR D.E., GERNER SMIDT P.,
NACHAMKIN I., 2001. Quinolone and macrolide resistance in
Campylobacter jejuni and C. coli: resistance mechanisms and trends in
human isolates. Emergent Infect. Dis., 7: 24-34.
13. FERNANDEZ H., MANSILLA M., GONZALEZ V., 2000.
Antimicrobial susceptibility of Campylobacter jejuni subsp. jejuni
assessed by E-test and double dilution agar method in Southern Chile.
Mem. Inst. Oswaldo Cruz, 95: 247-249.
14. FUNKE G., LUTHY-HOTTENSTEIN J., ALTWEGG M., 1993. The E
Test for antimicrobial susceptibility testing of clinical Campylobacter
jejuni and Campylobacter coli. Med. Microbiol. Lett., 2: 168-175.
15. GAUDREAU C., GILBERT H., 1998. Antimicrobial resistance of
clinical strains of Campylobacter jejuni subsp. jejuni isolated from 
1985 to 1997 in Quebec, Canada. Antimicrob. Agents Chemother., 42:
2106-2108.
16. GAUNT P.N., PIDDOCK L.J., 1996. Ciprofloxacin resistant
Campylobacter spp. in humans: an epidemiological and laboratory
study. J. Antimicrob. Chemother., 37: 747-757.
17. HOGE C.W., GAMBEL J.M., SRIJAN A., PITARANGSI C.,
ECHEVERRIA P., 1998. Trends in antibiotic resistance among diarrheal
pathogens isolated in Thailand over 15 years. Clin. Infect. Dis., 26:
341-345.
18. HUMPHREY T.J., MARTIN K.W., SLADER J., DURHAM K., 2001.
Campylobacter spp. in the kitchen: spread and persistence. Symp. ser.
(Society For Applied Microbiology), 30: 115S-120S.
19. LI C.C., CHIU C.H., WU J.L., HUANG Y.C., LIN T.Y., 1998.
Antimicrobial susceptibilities of Campylobacter jejuni and coli by using
E-test in Taiwan. Scand. J. Infect. Dis., 30: 39-42.
20. LUO N.P., BABOO K.S., MWENYA D., DIAB A., PERERA C.U.,
CUMMINGS C., DUPONT H.L., MURPHY J.R., ZUMLA A., 1996.
Isolation of Campylobacter species from Zambian patients with acute
diarrhoea. East Afr. Med. J., 73: 395-396.
21. MCDERMOTT P.F., BODEIS S.M., ENGLISH L.L., WHITE D.G.,
WALKER R.D., ZHAO S., SIMJEE S., WAGNER D.D., 2002.
Ciprofloxacin resistance in Campylobacter jejuni evolves rapidly in
chickens treated with fluoroquinolones. J. Infect. Dis., 185: 837-840.
22. NIELSEN E.M., NIELSEN N.L., 1999. Serotypes and typability of
Campylobacter jejuni and Campylobacter coli isolated from poultry
products. Int. J. Food Microbiol., 46: 199-205.
23. ONO K., YAMAMOTO K., 1999. Contamination of meat with
Campylobacter jejuni in Saitama, Japan. Int. J. Food Microbiol., 47:
211-219.
24. OSANO O., ARIMI S.M., 1999. Retail poultry and beef as sources of
Campylobacter jejuni. East Afr. Med. J., 76: 141-143.
25. PIDDOCK L.J.V., 1995. Quinolone resistance and Campylobacter
spp. J. Antimicrob. Chemother., 36: 891-898.
26. PIDDOCK L.J.V., 2002. Fluoroquinolone resistance in Salmonella
serovars isolated from humans and food animals. FEMS Microbiol. Rev.,
26: 3-16.
27. RAUTELIN H., RENKONEN O.V., KOSUNEN T.U., 1991. Emergence
of fluoroquinolone resistance in Campylobacter jejuni and
Campylobacter coli in subjects from Finland. Antimicrob. Agents
Chemother., 35: 2065-2069.
28. REFREGIER-PETTON J., ROSE N., DENIS M., SALVAT G., 2001. Risk
factors for Campylobacter spp. contamination in French broiler-chicken
flocks at the end of the rearing period. Prev. vet. Med., 50: 89-100.
29. SAENZ Y., ZARAZAGA M., LANTERO M., GASTANARES M.J.,
BAQUERO F., TORRES C., 2000. Antibiotic resistance in Campylobacter
strains isolated from animals, foods, and humans in Spain in 1997-1998.
Antimicrob. Agents Chemother., 44: 267-271.
30. SANCHEZ R., FERNANDEZ BACA V., DIAZ M.D., MUNOZ P.,
RODRIGUEZ CREIXEMS M., BOUZA E., 1994. Evolution of
susceptibilities of Campylobacter spp. to quinolones and macrolides.
Antimicrob. Agents Chemother., 38: 1879-1882.
31. SHIH D.Y., 2000. Isolation and identification of enteropathogenic
Campylobacter spp. from chicken samples in Taipei. J. Food Prot., 63:
304-308.
32. SMITH S.I., SANSA T.I., COKER A.O., 1999. Antibiotic susceptibility
patterns and beta-lactamase production of animal and human isolates of
Campylobacter in Lagos, Nigeria. Z. Naturforsch. [C], 54: 583-586.
33. SOUSSY C.J., CARRET G., CAVALLO J.D., CHARDON H., CHIDIAC
C., CHOUTET P., COURVALIN P., DABERNAT H., DRUGEON H.,
DUBREUIL L., GOLDSTEIN F., JARLIER V., LECLERCQ R., NICOLAS-
CHANOINE M.H., PHILIPPON A., QUENTIN C., ROUVEIX B., SIROT J.,
2000. Antibiogram Committee of the French Microbiology Society,
Report 2000-2001, 48: 832-871.
34. TAJADA P., GOMEZ GRACES J.L., ALOS J.I., BALAS D., COGOLLOS
R., 1996. Antimicrobial susceptibilities of Campylobacter jejuni
and Campylobacter coli to 12 beta-lactam agents and combinations 
with beta-lactamase inhibitors. Antimicrob. Agents Chemother., 40:
1924-1925.
35. TALHOUK R.S., EL DANA R.A., ARAJ G.F., BARBOUR E., HASHWA
F., 1998. Prevalence, antimicrobial susceptibility and molecular
characterization of Campylobacter isolates recovered from humans and
poultry in Lebanon. J. Med. Liban., 46: 310-316.
36. TENOVER F.C., BAKER C.N., FENNEL C.L., 1992. Antimicrobial
resistance in Campylobacter species. In: Nachamkin I., Blaser M.J.,
Tompkins L.S., Eds, Washington DC, USA, ASM Press, p. 66-73.
37. THWAITES R.T., FROST J.A., 1999. Drug resistance in
Campylobacter jejuni, C. coli, and C. lari isolated from humans in north
west England and Wales, 1997. J. clin. Pathol., 52: 812-814.
38. VAN DEN BOGAARD A.E., STOBBERINGH E.E., 2000.
Epidemiology of resistance to antibiotics. Links between animals and
humans. Int. J. Antimicrob. Agents, 14: 327-335.
39. VAN LOOVEREN M., DAUBE G., DE ZUTTER L., DUMONT J.M.,
LAMMENS C., WIJDOOGHE M., VANDAMME P., JOURET M.,
CORNELIS M., GOOSSENS H., 2001. Antimicrobial susceptibilities of
Campylobacter strains isolated from food animals in Belgium. J.
Antimicrob. Chemother., 48: 235-240.
40. WHITE P.L., BAKER A.R., JAMES W.O., 1997. Strategies to control
Salmonella and Campylobacter in raw poultry products. Revue sci. tech.
Off. int. Epizoot., 16: 525-541.
Reçu le 15.07.2003, accepté le 29.10.2003
■
PA
TH
O
LO
G
IE
 I
N
FE
C
TI
EU
SE
  c
om
m
un
ic
at
io
n
Campylobacter Antimicrobial Susceptibility in Senegal
R
ev
ue
 É
le
v.
 M
éd
. v
ét
. P
ay
s 
tr
op
., 
20
02
, 5
5 
(4
) :
 2
59
-2
64
264
Résumé
Cardinale E., Dromigny J.-A., Tall F., Ndiaye M., Konte M.,
Perrier Gros-Claude J.-D. Sensibilité aux antibiotiques de
souches de Campylobacter isolées de carcasses de poulets au
Sénégal
La résistance de Campylobacter aux antibiotiques constitue
aujourd’hui un problème émergent de santé publique dans les
pays industrialisés, mais, en revanche, peu d’informations sont
disponibles sur le sujet dans les pays en développement. Pour
évaluer la sensibilité des souches de Campylobacter au Séné-
gal, des prélèvements de peau ont été réalisés sur 250 car-
casses de poulet entre janvier 2001 et octobre 2002. Parmi les
204 souches de Campylobacter isolées, deux espèces ont été
identifiées : C. jejuni (59 p. 100) et C. coli (41 p. 100). La sen-
sibilité in vitro à cinq antibiotiques (amoxicilline, amoxicilline
et acide clavulanique, erythromycine, acide nalidixique et
ciprofloxacine) a été déterminée par la méthode du E-test.
L’étude des concentrations minimales inhibitrices (CMI) a
montré que 34 p. 100 des isolats étaient résistants à la cipro-
floxacine avec un haut niveau de résistance (CMI ≥ 32 mg/l)
dans 25 p. 100 des deux espèces. Une résistance croisée entre
l’acide nalidixique et la ciprofloxacine a été constatée dans 
96 p. 100 des souches résistantes aux quinolones. Le niveau
de résistance à l’amoxicilline a été statistiquement plus impor-
tant pour C. coli que pour C. jejuni (20,2 p. 100 contre 
10,8 p. 100) mais toutes les souches ont été sensibles à l’asso-
ciation amoxicilline-acide clavulanique. Les deux espèces ont
présenté une faible résistance à l’érythromycine. Un phéno-
type de multirésistance à trois des antibiotiques testés a été
identifié dans 9,8 p. 100 des souches : 15,5 p. 100 pour 
C. coli et 5,8 p. 100 pour C. jejuni. Aucune souche ne s’est
avérée résistante à quatre antibiotiques ou plus. Des études
complémentaires apparaissent nécessaires pour évaluer la
résistance aux antibiotiques des Campylobacter isolés chez
l’homme et chez l’animal afin de contrôler l’émergence de
nouvelles souches multirésistantes au Sénégal.
Mots-clés : Poulet – Campylobacter – Résistance aux antibio-
tiques – Sénégal.
Resumen
Cardinale E., Dromigny J.-A., Tall F., Ndiaye M., Konte M.,
Perrier Gros-Claude J.-D. Susceptibilidades anti-microbianas
de cepas de Campylobacter aisladas de carcasas de pollos en
Senegal
La resistencia de Campylobacter a los antibióticos constituye
hoy en día un problema emergente de salud pública en los
países industrializados, sin embargo, existe poca información
disponible en los países en vías de desarrollo. Para evaluar la
sensibilidad de las cepas de Campylobacter en Senegal, se
obtuvieron muestras de piel en 250 carcasas de pollo, entre
enero 2001 y octubre 2002. Entre las 204 cepas de Campylo-
bacter aisladas, se identificaron dos especies: C. jejuni (59%)
y C. coli (41%). Se determinó la sensibilidad in vitro a 5 anti-
bióticos (amoxicilina, amoxicilina y ácido clavulánico, eritro-
micina, ácido nalidíxico y ciprofloxacina), mediante el
método de E-test. El estudio de las CMI mostró que 34% de
los aislamientos fueron resistentes a la ciprofloxacina con un
alto nivel de resistencia (CMI ≥ 32 mg/l), en 25% de las dos
especies. Mediante el “E-test”, se observó una resistencia cru-
zada entre el ácido nalidíxico y la ciprofloxacina en 96% de
las cepas resistentes a las quinolonas. El grado de resistencia a
la amoxicilina fue significativamente más importante para C.
coli que para C. jejuni (20,2% contra 10,8%), pero todas las
cepas fueron sensibles a la asociación amoxicilina-ácido cla-
vulánico. Las dos especies presentaron una baja resistencia a
la eritromicina. Se identificó un fenotipo multi-resistente a tres
de los antibióticos en 9,8% de las cepas: 15,5% para C. coli y
5,8% para C. jejuni. Ninguna cepa se mostró resistente a más
de cuatro antibióticos. Parece necesaria la realización de estu-
dios complementarios, con el fin de evaluar la resistencia a
los antibióticos de los Campylobacter aislados en el hombre y
en el animal, para controlar el surgimiento de nuevas cepas
resistentes en Senegal.
Palabras clave: Pollo – Campylobacter – Resistencia a las anti-
bióticos – Senegal.
